Open in interactive viewer → charts, metric popovers & call review

Beachbody Cut Its Way to Profit — and Ran Out of Customers

A twelfth straight positive-EBITDA quarter and a breakeven slashed from $900M to $125M, set against Q4 revenue guided to a fresh all-time low while the nutrition pivot waits on shelf-reset calendars it cannot control.
BODI · Earnings Call · 2026-11-10

The Clean Read Arrived — and It Was Ugly

For two quarters management sold investors on a specific promise: once the legacy multilevel-marketing tail burned off, the third quarter of 2026 would finally be a clean, apples-to-apples read on the new company. On the August call, Mark Goldston was emphatic: “Most of that's going to be clean by Q3... it will be a pure read of Q3 '26 versus Q3 '25.” — Mark Goldston, Executive Chairman · 2026-05-12 The read came in, and it was not kind. Revenue of $45.2 million fell 24.5% year over year and 8.9% sequentially, and the fourth-quarter guide of $38–42 million points to another step down — versus the $56 million booked in last year's Q4. Goldston himself framed the quarter around the admission that the growth half of the story is broken: “the growth turnaround, which is taking a little longer than we expected largely because of retail timing.” — Mark R. Goldston, Executive Chairman · 2026-11-10 More bluntly, in Q&A: “our rate of attrition has exceeded our rate of addition.” — Mark R. Goldston, Executive Chairman · 2026-11-10 That is the whole dossier in one sentence.

A Cost Machine Running on Fumes

The profitability story is real, and it deserves its due. A 71% gross margin, $6.4 million of adjusted EBITDA at a 14.1% margin, positive operating and net income — the fifth consecutive quarter of each. The October restructuring cut the cost base by more than $30 million, taking the adjusted-EBITDA breakeven level to roughly $125 million from over $900 million four years ago. That is a genuinely impressive piece of surgery on a shrinking body. But the shape of the top line is the tell. The company's sales base has eroded for six straight years: Total revenue has fallen about 75% from its 2020 peak, and margin gains are increasingly the only lever left. Gross margin, at roughly 72%, is already near the top of its range: gross margin sits near 72% after a multi-year climb from the low 60s. You cannot cut your way to growth, and the company now appears to be discovering that arithmetic in public.

Nutrition Is the New Religion; Retail Is the Same Old Clock

Management has recast Beachbody as a nutrition-first multichannel company, leaning on the $164 billion supplement category against a $13 billion digital-fitness pond. The new-product push is real and visible in this quarter's language: energy drink launches (Insanity Liquid Shock and the P90X line), a broadened nutritional supplement portfolio, a Shopify-fronted DTC funnel, and even a new "Body 365" daily-habit program. Carl Daikeler is mobilizing a creator army of affiliates and influencers to seed reviews — the same playbook that built the company, repurposed. But the growth lever everyone is waiting on is retail, and retail runs on a calendar Beachbody does not own. The planogram cycle — the once-or-twice-yearly shelf reset — is the gating item, and management spent an unusual amount of the call apologizing for its own impatience. Goldston noted the company is in 181 Sprouts stores and 481 Vitamin Shoppe doors, but conceded “You do not get in intermittently by and large. You must wait for the reset cycle.” — Mark R. Goldston, Executive Chairman · 2026-11-10 The keyword data echoes the stall: Vitamin Shoppe was the company's single hottest keyword last quarter; this quarter it was among the sharpest decliners, and even "reordered" flipped negative — the enthusiasm of the retail narrative is cooling exactly as it should be converting into volume. The pitch now is that the loaded pipeline pays off later. Daikeler: “we are loaded for bear as we go into the first and second quarter of next year.” — Carl D. Daikeler, Co-founder and Chief Executive Officer · 2026-11-10 Investors have heard forward-loaded optimism from this team before; what they want is the crossover the company has never achieved — Goldston cited a sub-10% crossover from digital subscribers into supplements against a ~61% market norm. That gap is the bull case, and it is also the reason the pivot exists.

Cash, Covenant, and a Very Tight Clock

The balance sheet is the reason this is a survival story rather than a growth story. Cash of $27.5 million against $22.9 million of debt leaves a net cash position of $4.6 million, and the amended credit agreement stops testing covenants only while cash stays above $22.5 million. Nine-month free cash flow was negative $12.1 million, driven partly by a $5 million inventory build — inventory management now intends to push off its own books via a turnkey manufacturing model, freeing roughly $8 million of raw materials over time, part of a $34 million total spending-reduction program. That cushion is thin. The fundamentals show the fragility plainly: free cash flow (less stock comp) has turned negative again, and effective net cash is down to single-digit millions — a far cry from the $43 million it held in 2022. There is dry powder in the rhetoric, and the October cuts genuinely widened the runway, but the margin for error is now measured in quarters, not years.

The Verdict

The stock tells you what the call could not. Shares are down roughly 68% over the last 90 days, and the tape shows a brief July spike to $11.24 that has since given back more than 70% — a speculative flutter around the pivot, then a collapse as the clean quarter revealed structural shrinkage. This is a company that has masterfully engineered a profitable shell around a shrinking business and is now betting that a shelf-reset cycle and an energy-drink launch can restart the top line before the cash buffer runs out. The rate of attrition is the number to watch; until it flips below the rate of addition, everything else is cost discipline dressed as strategy.